real-time news and commentary for investors
Friday, Aug 30
Tekmira Pharmaceuticals gains after two articles are published in peer journals highlighting its Lipid Nanoparticle Technology
- Tekmira Pharmaceuticals (TKMR +0.6%) bucks a weak tape to trade higher today after saying it's had two articles published in peer-reviewed scientific journals - the Journal of Infectious Diseases and New England Journal of Medicine - highlighting positive results enabled by TKMR's lipid nanoparticle technology.
- The company says the arcticles provide "robust proof of concept" for RNAi therapy, indicating the first report of complete post-exposure protection against the most pathogenic strain of Marburg virus.
- TKMR President and CEO Dr. Mark J. Murray says the findings build upon the company's work in infectious diseases – including its TKM-Ebola program, which is entering a Phase I clinical trial early in 2014 – and provides a foundation for future infectious disease therapeutics.